Who
Rebecca Chambers
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Veracyte; Director, Alamar Biosciences; Director, Inari Medical; Chief Financial Officer, Outset Medical.
In numbers
- Trades disclosed
- 88
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $7.3M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 15 Mar 2021
- Last trade
- 4 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $106K2,477 at $42.81 | filing |
| 4 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $51K1,175 at $43.71 | filing |
| 4 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $106K2,477 at $42.81 | filing |
| 4 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $51K1,175 at $43.71 | filing |
| 2 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $162K3,603 at $44.88 | filing |
| 2 Sep 2026filed 4 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $162K3,603 at $44.88 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $79K1,600 at $49.28 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $98K1,961 at $50.09 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $79K1,600 at $49.28 | filing |
| 4 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $98K1,961 at $50.09 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $177K3,693 at $47.80 | filing |
| 2 Jun 2026filed 4 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code F | $177K3,693 at $47.80 | filing |
| 20 Apr 2026filed 20 Apr 2026 | ALMR Alamar Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code J | —140,612 at $0.00 | filing |
| 20 Apr 2026filed 20 Apr 2026 | ALMR Alamar Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code J | —140,612 at $0.00 | filing |
| 20 Apr 2026filed 20 Apr 2026 | ALMR Alamar Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code J | —140,612 at $0.00 | filing |
| 20 Apr 2026filed 20 Apr 2026 | ALMR Alamar Biosciencesoption or derivative · Life-science tools | SEC FORM 4 Code J | —140,612 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —36,181 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —13,157 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —36,181 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —13,157 at $0.00 | filing |
News
Veracyte's Decipher Can Help Men Detect Prostate CancerVCYT · finanzen.ch · 23 Oct 2026Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerVCYT · manilatimes.net · 23 Oct 2026
0 headlines in the last 90 days name Rebecca Chambers; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.